AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £500.27m
- £516.94m
- £55.04m
Allergy Therapeutics - Update on funding
Brief: Allergy Therapeutics Extends Cash Runway Into Late-October
Brief: Allergy Therapeutics Says Further Advancement Via Patient Cohorts In Phase I/IIa VLP Peanut PROTECT Trial
Brief: Allergy Therapeutics Extends Cash Runway Into Late September
Brief: Allergy Therapeutics Outlook HY Revenue GBP 21.6 Mln
Brief: Allergy Therapeutics Sees H2 Revenue At £21.6M
Allergy Therapeutics - Trading update for the year ended 30 June 2024
Allergy Therapeutics - Launch of new Company Long Term Incentive Plan
Allergy Therapeutics - Appointment of Non-Executive Director
Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
RCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI
Allergy Therapeutics - Director Resignation
Brief: Allergy Therapeutics Sees H2 Sales Slightly Higher Than Previous Year
Brief: Allergy Therapeutics Extends Cash Runway Into Q1 Of FY25
Allergy Therapeutics - Update on funding
Allergy Therapeutics - Interim Results for six months ended 31 Dec 2023
Allergy Therapeutics - VLP Peanut PROTECT Trial Update
RCS - Allergy Therapeutics - VLP Peanut PROTECT Trial Update
Brief: Allergy Therapeutics Appoints Shaun Furlong As Executive Director